Stock Track | BioNTech Soars 5.04% as Company Unveils Promising Oncology Data for AACR 2025 Presentation

Stock Track

25 Apr

BioNTech SE (NASDAQ: BNTX) shares surged 5.04% in Thursday's trading session following the company's announcement of its upcoming presentation at the American Association for Cancer Research (AACR) Annual Meeting. The biotechnology firm is set to showcase data from its diverse oncology pipeline, including mRNA cancer immunotherapies and next-generation immunomodulators, at the prestigious event scheduled for April 25-30, 2025 in Chicago.

Investors responded positively to the news, which highlights BioNTech's progress in advanced priority oncology programs and its strategic combination approach in cancer treatment. The company will present data on several key assets, including BNT327, a bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization, and BNT116, an mRNA cancer immunotherapy candidate for non-small cell lung cancer (NSCLC).

The strong market reaction underscores the growing investor confidence in BioNTech's oncology pipeline and its potential to diversify beyond its successful COVID-19 vaccine. With over 20 active Phase 2 and Phase 3 clinical trials across multiple solid tumor indications, the company is positioning itself as a multi-product oncology leader. BioNTech's focus on innovative combination therapies and its expectation of multiple data readouts in 2025 and 2026 appear to be driving optimism among shareholders, contributing to today's significant stock price increase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1146765866"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1146765866\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1146765866?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-25 04:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146765866","market":"us","top_or_hot":-1,"title":"Stock Track | BioNTech Soars 5.04% as Company Unveils Promising Oncology Data for AACR 2025 Presentation","media":"Stock Track","content":"<p>BioNTech SE (NASDAQ: BNTX) shares surged 5.04% in Thursday's trading session following the company's announcement of its upcoming presentation at the American Association for Cancer Research (AACR) Annual Meeting. The biotechnology firm is set to showcase data from its diverse oncology pipeline, including mRNA cancer immunotherapies and next-generation immunomodulators, at the prestigious event scheduled for April 25-30, 2025 in Chicago.</p>\n\n<p>Investors responded positively to the news, which highlights BioNTech's progress in advanced priority oncology programs and its strategic combination approach in cancer treatment. The company will present data on several key assets, including BNT327, a bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization, and BNT116, an mRNA cancer immunotherapy candidate for non-small cell lung cancer (NSCLC).</p>\n\n<p>The strong market reaction underscores the growing investor confidence in BioNTech's oncology pipeline and its potential to diversify beyond its successful COVID-19 vaccine. With over 20 active Phase 2 and Phase 3 clinical trials across multiple solid tumor indications, the company is positioning itself as a multi-product oncology leader. BioNTech's focus on innovative combination therapies and its expectation of multiple data readouts in 2025 and 2026 appear to be driving optimism among shareholders, contributing to today's significant stock price increase.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioNTech Soars 5.04% as Company Unveils Promising Oncology Data for AACR 2025 Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioNTech Soars 5.04% as Company Unveils Promising Oncology Data for AACR 2025 Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-04-25 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech SE (NASDAQ: BNTX) shares surged 5.04% in Thursday's trading session following the company's announcement of its upcoming presentation at the American Association for Cancer Research (AACR) Annual Meeting. The biotechnology firm is set to showcase data from its diverse oncology pipeline, including mRNA cancer immunotherapies and next-generation immunomodulators, at the prestigious event scheduled for April 25-30, 2025 in Chicago.</p>\n\n<p>Investors responded positively to the news, which highlights BioNTech's progress in advanced priority oncology programs and its strategic combination approach in cancer treatment. The company will present data on several key assets, including BNT327, a bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization, and BNT116, an mRNA cancer immunotherapy candidate for non-small cell lung cancer (NSCLC).</p>\n\n<p>The strong market reaction underscores the growing investor confidence in BioNTech's oncology pipeline and its potential to diversify beyond its successful COVID-19 vaccine. With over 20 active Phase 2 and Phase 3 clinical trials across multiple solid tumor indications, the company is positioning itself as a multi-product oncology leader. BioNTech's focus on innovative combination therapies and its expectation of multiple data readouts in 2025 and 2026 appear to be driving optimism among shareholders, contributing to today's significant stock price increase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"","article_id":"1146765866","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146765866","pubTimestamp":1745524827,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BioNTech SE  shares surged 5.04% in Thursday's trading session following the company's announcement of its upcoming presentation at the American Association for Cancer Research  Annual Meeting. The biotechnology firm is set to showcase data from its diverse oncology pipeline, including mRNA cancer immunotherapies and next-generation immunomodulators, at the prestigious event scheduled for April 25-30, 2025 in Chicago.Investors responded positively to the news, which highlights BioNTech's progres","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE"},"translate_title":"BioNTech在AACR 2025演示中公布了有希望的肿瘤学数据，股价飙升5.04%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1},"content_text":"BioNTech SE (NASDAQ: BNTX) shares surged 5.04% in Thursday's trading session following the company's announcement of its upcoming presentation at the American Association for Cancer Research (AACR) Annual Meeting. The biotechnology firm is set to showcase data from its diverse oncology pipeline, including mRNA cancer immunotherapies and next-generation immunomodulators, at the prestigious event scheduled for April 25-30, 2025 in Chicago.\nInvestors responded positively to the news, which highlights BioNTech's progress in advanced priority oncology programs and its strategic combination approach in cancer treatment. The company will present data on several key assets, including BNT327, a bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization, and BNT116, an mRNA cancer immunotherapy candidate for non-small cell lung cancer (NSCLC).\nThe strong market reaction underscores the growing investor confidence in BioNTech's oncology pipeline and its potential to diversify beyond its successful COVID-19 vaccine. With over 20 active Phase 2 and Phase 3 clinical trials across multiple solid tumor indications, the company is positioning itself as a multi-product oncology leader. BioNTech's focus on innovative combination therapies and its expectation of multiple data readouts in 2025 and 2026 appear to be driving optimism among shareholders, contributing to today's significant stock price increase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}